粪便钙卫蛋白水平与克罗恩病进展之间的关联
本回顾性研究纳入英国爱丁堡一家三级医疗中心2003年至2015年诊治的918例克罗恩病患者(随访4218患者年,中位50.6个月),分析粪便钙卫蛋白水平与蒙特利尔行为分型进展、住院和切除复合结局的关联。结果显示,指数就诊时钙卫蛋白升高与后续疾病进展相关,且不依赖症状或病变部位;多变量分析中,115 μg/g的截断值识别达到终点患者的风险比(HR)为2.4(95%CI 1.8-3.1;P < .0001)。
要点
- 指数就诊时粪便钙卫蛋白升高与后续克罗恩病进展相关,独立于症状或病变部位。
- 达到复合终点者指数就诊时钙卫蛋白中位432 μg/g(IQR 1365-998 μg/g),未达到者为180 μg/g(IQR 50-665 μg/g)。
- 多变量分析中,115 μg/g截断值识别达到终点患者的HR为2.4(95%CI 1.8-3.1;P < .0001)。
核心结论
- 在克罗恩病患者的回顾性分析中,常规监测期间测量的粪便钙卫蛋白可识别疾病进展风险患者,且不依赖症状或病变部位。
- 因此,对无症状患者筛查黏膜炎症并追求炎症完全消退是重要的。
研究设计与样本
- 回顾性研究,纳入英国爱丁堡一家三级医疗中心2003年至2015年诊治的918例克罗恩病患者,随访4218患者年,中位随访50.6个月(IQR 32.8-76.0个月)。
- 纳入标准为诊断后3个月或更长时间内至少有1次粪便钙卫蛋白测量。
- 收集临床数据和粪便钙卫蛋白测量值,分析与美国蒙特利尔行为分型进展、住院和切除复合结局相关的因素。
主要发现
- 指数就诊时粪便钙卫蛋白水平升高与后续克罗恩病进展相关,独立于症状或病变部位。
- 达到复合终点者指数就诊时粪便钙卫蛋白中位水平为432 μg/g(IQR 1365-998 μg/g),未达到者为180 μg/g(IQR 50-665 μg/g)。
- 多变量分析中,115 μg/g的钙卫蛋白截断值识别达到终点患者的HR为2.4(95%CI 1.8-3.1;P < .0001)。
临床怎么用
- 原文结论指出,常规监测期间测量的粪便钙卫蛋白可识别克罗恩病进展风险患者,且不依赖症状或病变部位。
- 原文结论指出,对无症状患者筛查黏膜炎症并追求炎症完全消退是重要的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Mucosal healing is associated with improved outcomes in patients with Crohn's disease (CD), but assessment typically requires ileocolonoscopy. Calprotectin can be measured in fecal samples to determine luminal disease activity in place of endoscopy-this measurement is an important component of the treat-to-target strategy. We investigated whether levels of fecal calprotectin are associated with subsequent CD progression. METHODS: We performed a retrospective study of 918 patients with CD (4218 patient-years of follow-up evaluation; median, 50.6 mo; interquartile range [IQR], 32.8-76.0 mo) managed at a tertiary medical center in Edinburgh, United Kingdom, from 2003 through 2015. Patients were included if they had 1 or more fecal calprotectin measurements made 3 months or more after their diagnosis. We collected clinical data and fecal calprotectin measurements and analyzed these data to identify factors associated with a composite outcome of progression in Montreal behavior, hospitalization, and resection. RESULTS: An increased level of fecal calprotectin at the index visit was associated with subsequent progression of CD, independent of symptoms or disease location. The median level of fecal calprotectin at the index visit was 432 μg/g (IQR, 1365-998 μg/g) in patients who reached the composite end point vs 180 μg/g (IQR, 50-665 μg/g) in patients who did not. In multivariable analysis, a cut-off value of 115 μg/g calprotectin identified patients who met the end point with a hazard ratio of 2.4 (95% CI, 1.8-3.1; P < .0001). CONCLUSIONS: In a retrospective analysis of patients with CD, we found that measurements of fecal calprotectin made during routine monitoring can identify patients at risk for disease progression, independent of symptoms or disease location. It is therefore important to screen asymptomatic patients for mucosal inflammation and pursue complete resolution of inflammation.
引用
- Kennedy NA, Jones GR, Plevris N, et al. Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease. Clin Gastroenterol Hepatol. 2019. PMID: 30772585. doi:10.1016/j.cgh.2019.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。